Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study)

VONCENTO (CSL Behring Gmbh, Marburg, Germany) is a plasma-derived, high concentration, lower volume [relative to HAEMATE P (CSL Behring)], high-purity von Willebrand factor (VWF)/factor VIII (FVIII) concentrate with a VWF/FVIII ratio similar to HAEMATE P. This open-label, multicentre study investiga...

Descripción completa

Detalles Bibliográficos
Autores principales: Lissitchkov, Toshko J., Buevich, Evgeny, Kuliczkowski, Kazimierz, Stasyshyn, Oleksandra, Cerqueira, Monica Hermida, Klukowska, Anna, Joch, Christine, Seifert, Wilfried
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams And Wilkins 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312726/
https://www.ncbi.nlm.nih.gov/pubmed/27203734
http://dx.doi.org/10.1097/MBC.0000000000000568

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312726/
https://www.ncbi.nlm.nih.gov/pubmed/27203734
http://dx.doi.org/10.1097/MBC.0000000000000568

Ejemplares similares